Format

Send to

Choose Destination
J Clin Neuromuscul Dis. 2018 Jun;19(4):211-216. doi: 10.1097/CND.0000000000000208.

Case of Anti-Single Recognition Particle-Mediated Necrotizing Myopathy After Influenza Vaccination.

Author information

1
Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
2
Department of Pathology and Laboratory Medicine, Rutgers-New Jersey Medical School, Newark, NJ.
3
Department of Rheumatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
4
Rutgers Robert Wood Johnson Medical School, Piscataway, NJ.

Abstract

Immune-mediated necrotizing myopathy is a very rare inflammatory disease affecting skeletal muscles. Immune-mediated necrotizing myopathy may be associated with myositis-specific autoantibodies including anti-single recognition particle and anti-3-hydroxy-3- methylglutaryl-coenzyme A reductase, infectious agents (HIV or hepatitis C), other connective tissue disorders (such as scleroderma), and malignancy. We reported a 28-year-old healthy woman presented with subacute onset ascending muscle weakness 2 weeks after an annual influenza vaccination. Cerebral Spinal Fluid study showed normal cell counts with elevated protein and nerve conduction study showed reduced diffuse compound muscle action potential amplitudes suggesting a diagnosis of Guillain-Barré syndrome. Despite treatment using intravenous immunoglobulin, her condition continued to get worse with new bulbar and respiratory muscle weakness. Eventually, the diagnosis of anti-single recognition particle-mediated necrotizing myopathy was made based on elevated creatine kinase, thigh magnetic resonance imaging, muscle biopsy, and positive antibody testing. Our patient responded to the combination of intravenous immunoglobulin, prednisone, and anti-CD20 monoclonal antibody, rituximab.

PMID:
29794576
DOI:
10.1097/CND.0000000000000208
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center